Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hyaluronic acid derivative and drug containing the same

a technology of hyaluronic acid and derivatives, which is applied in the direction of biocide, drug composition, transportation and packaging, etc., can solve the problems of short time period for continuing the effect of nsaids and the method not becoming a basic remedy for arthritis

Inactive Publication Date: 2011-04-14
SEIKAGAKU KOGYO CO LTD
View PDF4 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The hyaluronic acid derivatives provide sustained pain relief and anti-inflammatory effects by maintaining effective drug concentrations at the joint site, reducing gastrointestinal adverse effects and offering a more effective treatment for arthritis compared to traditional oral administration.

Problems solved by technology

A method in which the problematic point as gastrointestinal adverse effects caused by the oral administration of NSAIDs is avoided by direct injection NSAIDs into the affected site can be considered Although theoretically, but for example, when NSAIDs are directly injected into the knee joint cavity, the period of time for continuing the effect of NSAIDs is short due to quick absorption, so that such a method is not adopted.
In addition, since NSAIDs themselves aim at alleviating or suppressing pain, such a method does not become a basic remedy for arthritis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hyaluronic acid derivative and drug containing the same
  • Hyaluronic acid derivative and drug containing the same
  • Hyaluronic acid derivative and drug containing the same

Examples

Experimental program
Comparison scheme
Effect test

examples

[0146]The present invention is described below more specifically based on Examples. However, there is no intention to limit the technical scope of the present invention by this.

[0147]In this connection, all of the hyaluronic acid and sodium hyaluronate used in the following Examples were purchased from Seikagaku Corporation.

[0148]Hereinafter, as the phosphate buffered saline (PBS), 5 mM PBS was used in the following Examples, unless otherwise indicated.

production examples

Reference Example 1

Synthesis of t-butoxycarbonyl-aminopropanol (Boc-NH(CH2)3OH) (Boc-aminopropanol)

[0150]In 10 ml of dichloromethane, 1.542 g (20.5 mmol) of aminopropanol was dissolved, and 10 ml of a 4.484 g (20.5 mmol) di-t-butyl dicarbonate (Boc2O) / dichloromethane solution was slowly added dropwise thereto under ice-cooling. Thereafter, the reaction solution was returned to room temperature and stirred for 2 hours and 40 minutes, disappearance of the starting materials was confirmed by thin layer chromatography (TLC), and then dichloromethane was evaporated under reduced pressure. The reaction quantitatively progressed, and an oily substance was obtained at a yield of 3.92 g. The structure was identified by 1H-NMR (CDCl3).

[0151]1H-NMR (500 MHz, CDCl3) δ (ppm)=1.46 (9H, s, Boc), 1.66 (2H, quant, —NHCH2CH2CH2O—), 3.27 (3H, m, —NHCH2CH2CH2O—), 3.66 (2H, m, —NHCH2CH2CH2O—), 4.91 (1H, br, CH2OH)

example 1

Synthesis of Aminopropanol-Ketoprofen Hydrochloride

1) Synthesis of Boc-Aminopropanol-Ketoprofen

[0152]In 14 ml of dichloromethane, 2.371 g (13.5 mmol) of Boc-aminopropanol and 3.441 g (13.5 mmol) of ketoprofen (manufactured by Tokyo Kasei Kogyo) were dissolved, and 323 mg (2.6 mmol) of 4-dimethylaminopyridine (DMAP) and 2.833 g (14.8 mmol) of water-soluble carbodiimide hydrochloride (WSCI.HCl) / 14 ml dichloromethane were added thereto in this order under ice-cooling. After returning to room temperature and stirring overnight, dichloromethane was evaporated under reduced pressure, and ethyl acetate was added thereto, followed by separation by washing with 5% citric acid twice, water, 5% sodium hydrogen carbonate twice, water and saturatedbrine consecutively. After dehydration drying with sodium sulfate, ethyl acetate was evaporated under reduced pressure to give 5.430 g of the titled compound (yield 98%). The structure was identified by 1H-NMR (CDCl3).

[0153]1H-NMR (500 MHz, CDCl3) δ (p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A hyaluronic acid derivative in which an anti-inflammatory drug is bound to hyaluronic acid through a covalent bond via a spacer having a biodegradable region, and a production process thereof.

Description

TECHNICAL FIELD[0001]The present invention relates to hyaluronic acid derivatives to which a non-steroidal anti-inflammatory drug or a disease-modifying anti-rheumatic drug is introduced via a spacer which is biodegradable, and production methods thereof.BACKGROUND ART[0002]A sodium hyaluronate solution is used as a therapeutic agent for arthritis such as osteoarthritis of knee (OA) or rheumatoid arthritis of knee (RA). The sodium hyaluronate solution is generally used as injections by the direct administration to the affected knee joints, and shoulder joints, and frequently used for the purpose of improving functional disorders and suppressing pain caused by the arthritis.[0003]Non-steroidal anti-inflammatory drugs (hereinafter also referred to as “NSAIDs” or “NSAID”) and disease-modifying anti-rheumatic drugs (hereinafter also referred to as “DMARD”), which improve morbid states such as articular rheumatism, are also used as agents for suppressing or alleviating pains caused by su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/728C08B37/08A61P29/00B65D69/00A61K9/08A61K31/192A61K31/196A61K31/405A61K31/5415A61K31/60A61K45/00A61K47/18A61K47/36A61K47/48A61P19/02A61P29/02
CPCA61K31/192A61K31/196A61K31/405A61K47/481A61K31/60A61K31/728A61K47/4823A61K31/5415A61K47/55A61K47/61A61P19/02A61P29/00A61P29/02C08B37/0072
Inventor MIYAMOTO, KENJIYASUDA, YOUSUKEYOSHIOKA, KEIJI
Owner SEIKAGAKU KOGYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com